Gujarat Terce Laboratories Quarterly Results for Trading Insights
In Sept 2021, Gujarat Terce Laboratories (GUJTERC) reported revenue ₹10 Cr and net profit ₹0 Cr — revenue +42.9% YoY. Also explore Gujarat Terce Laboratories share price performance to track price trends across different timeframes.
GUJTERC Quarterly Results — Revenue, Profit & EPS Highlights
Gujarat Terce Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse GUJTERC financial statements for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹10 Cr in Sept 2021 (+0.0% vs Jun 2021, +42.9% vs Sept 2020)
- EBITDA of ₹1 Cr in Sept 2021 (-50.0% vs Jun 2021)
- Operating Margin of 5.0% in Sept 2021 (-11.0pp vs Jun 2021)
- Earnings Per Share of ₹0.61 in Sept 2021 (-71.8% vs Jun 2021)
Gujarat Terce Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUJTERC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2021 | Jun 2021 | Sept 2020 | Mar 2020 | Jun 2020 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 10 | 10 | 7 | 10 | 5 | - | 42.9% |
| Net Profit (₹ Cr) | 0 | 2 | 0 | -1 | 0 | - | - |
| EBITDA (₹ Cr) | 1 | 2 | 0 | 0 | 0 | - | - |
| EPS (₹) | 0.61 | 2.16 | -0.02 | 0.00 | -0.60 | - | - |
| Operating Margin (%) | 5.0% | 16.0% | 2.0% | -5.0% | -8.0% | - | - |
GUJTERC Share Price Trend — 1-Year Movement Across Quarterly Results
Gujarat Terce Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Gujarat Terce Laboratories screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUJTERC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gujarat Terce Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹454,122.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹114,691.88 Cr | 1374.1 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 518.5 |
All amounts in ₹ Crores